Meletios A. Dimopoulos, MD, on the Future of a Combination Therapy in Multiple Myeloma
Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma.
Meletios A. Dimopoulos, MD, discussed the reassuring aspects and future implications of the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.
Transcription:
It was reassuring to see that there was less gastrointestinal toxicity as compared to the STORM trial where selinexor was given as a single agent at higher doses. This is important as far as gastrointestinal tolerability which was a major problem in the single agent STORM trial. Also, it was reassuring to see that there was less peripheral neuropathy.
This combination could be evaluated in earlier phases of the disease especially in activity in patients with high-risk cytogenetics. It could be combined with anti-CD38 monoclonal antibodies to provide the quadruple that would include patient treatments and regimens with different mechanisms of action.
